Antihypertensive effect of an enzymatic hydrolysate from Styela clava flesh tissue in type 2 diabetic patients with hypertension
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ko, Seok-Chun | - |
dc.contributor.author | Jung, Won-Kyo | - |
dc.contributor.author | Lee, Seung-Hong | - |
dc.contributor.author | Lee, Dae Ho | - |
dc.contributor.author | Jeon, You-Jin | - |
dc.date.accessioned | 2021-08-11T14:24:19Z | - |
dc.date.available | 2021-08-11T14:24:19Z | - |
dc.date.issued | 2017-10 | - |
dc.identifier.issn | 1976-1457 | - |
dc.identifier.issn | 2005-6168 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/7176 | - |
dc.description.abstract | BACGROUND/OBJECTIVES: In this randomized, placebo-controlled, double-blind study, we evaluated the antihypertensive effects of enzymatic hydrolysate from Styela clava flesh tissue in patients with type 2 diabetes mellitus (T2DM) and hypertension. SUBJECTS/METHODS: S. clava flesh tissue hydrolysate (SFTH) (n = 34) and placebo (n = 22) were randomly allocated to the study subjects. Each subject ingested two test capsules (500 mg) containing powdered SFTH (SFTH group) or placebo capsules (placebo group) during four weeks. RESULTS: In the SFTH group, systolic and diastolic blood pressure decreased significantly 4 weeks after ingestion by 9.9 mmHg (P < 0.01) and 7.8 mmHg (P < 0.01), respectively. In addition, the SFTH group exhibited a significant decrease in hemoglobin A(lc) with a tendency toward improvement in homeostasis model assessment of insulin resistance, triglyceride, apolipoprotein B and plasma insulin levels after 4 weeks. No adverse effects were observed in other indexes, including biochemical and hematological parameters in both groups. CONCLUSION: The results of our study suggested that SFTH exerts a regulatory, antihypertensive effect in patients with T2DM and hypertension. | - |
dc.format.extent | 6 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | 한국영양학회 | - |
dc.title | Antihypertensive effect of an enzymatic hydrolysate from Styela clava flesh tissue in type 2 diabetic patients with hypertension | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.4162/nrp.2017.11.5.396 | - |
dc.identifier.scopusid | 2-s2.0-85030860165 | - |
dc.identifier.wosid | 000413391600006 | - |
dc.identifier.bibliographicCitation | Nutrition Research and Practice, v.11, no.5, pp 396 - 401 | - |
dc.citation.title | Nutrition Research and Practice | - |
dc.citation.volume | 11 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 396 | - |
dc.citation.endPage | 401 | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002270552 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Nutrition & Dietetics | - |
dc.relation.journalWebOfScienceCategory | Nutrition & Dietetics | - |
dc.subject.keywordPlus | KINASE AMPK ACTIVATION | - |
dc.subject.keywordPlus | INHIBITORY PEPTIDE | - |
dc.subject.keywordPlus | ACE-INHIBITOR | - |
dc.subject.keywordPlus | ECKLONIA-CAVA | - |
dc.subject.keywordPlus | ANGIOTENSIN | - |
dc.subject.keywordPlus | VASORELAXATION | - |
dc.subject.keywordPlus | OCTAPHLORETHOL | - |
dc.subject.keywordPlus | PURIFICATION | - |
dc.subject.keywordPlus | GLUCOSE | - |
dc.subject.keywordPlus | DIECKOL | - |
dc.subject.keywordAuthor | Aquatic organisms | - |
dc.subject.keywordAuthor | protein hydrolysates | - |
dc.subject.keywordAuthor | clinical trial | - |
dc.subject.keywordAuthor | antihypertensive agents | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.